SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Corporation Unprecedented Progression-Free Survival Benefit With Afatinib* Associated With Clinically Meaningful Improvements in Life-Limiting Lung Cancer Symptoms and Better Quality of Life